Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.

Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a …

6 days ago · Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Learn more …

Regeneron is a leading science and technology company dedicated to inventing, developing and commercializing life-transforming treatments for serious diseases.

5 days ago · Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company …

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.

1 day ago · Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an …

Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, …

WELCOME TO REGENERON . Select your country below to access more information about. Regeneron's commercial products

Apr 22, 2025 · (Reuters) -Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug developer Fujifilm Diosynth to expand its U.S. …